2 Stocks That Could Lead to a Market Recovery

Is America in recession? The country’s GDP has declined for two consecutive quarters, which as a general rule indicates a recession. But technically the definition of a recession is much more than that. Still, the country’s economy is not in the best shape, and hence investors never have trouble getting ready for an economic downturn.

With that in mind, let’s take a look at two healthcare stocks that can take you through these challenging times and beyond: johnson and johnson (JNJ -0.37%, And Bristol-Myers Squibbo (BMY -0.46%,,

JNJ Chart

jnj data by WiCharts.

johnson and johnson

When it comes to essential products consumers rely on even during an economic downturn, lifesaving drugs are hard to beat. Johnson & Johnson is right up the alley because the company’s pharmaceutical division is the largest by revenue. The healthcare giant boasts dozens of products, including many movies,

Some of the best-selling drugs include the cancer drugs Darzalex and Erleada and the immunosuppressants Stelara and Tremfya. The sales of all these products continue to grow well. Stelara, Darzalex, and Tremfya have made more than $1 billion to date, and Erleada should do so by the end of the year.

During the first quarter, Johnson & Johnson’s total sales rose 3% year over year to $24 billion. Although this does not sound impressive, it is worth noting that strengthen the US dollar Hurt the pharma giant’s revenue growth. On an operations basis, total sales of Johnson & Johnson grew 8% year over year.

In addition, the company’s worst-performing segment in terms of top-line operational growth was its consumer health unit, which it will convert to a stand-alone unit by the end of the year. Johnson & Johnson’s pharmaceutical segment reported sales of $13.3 billion, representing year-over-year growth of 12.3%.

Johnson & Johnson’s top-line growth is expected to improve as it focuses on its pharmaceutical unit and its medical device segment. Within the East, the company continues to earn new regulatory approvals thanks to its rich pipeline, which includes several frozen ongoing pipeline programs.

Within medical devices, Johnson & Johnson could lead the way in the promising robotic-assisted surgery (RAS) market in the coming years thanks to its RAS device, Ottawa. In other words, the company has plenty of growth avenues to exploit.

Another benefit of buying J&J shares: the company is a dividend king, continued to increase its payout for 59 years. dividend stocks are well equipped The market is ready to handle a downturn, and there’s another solid reason to consider this top pharma stock.

2. Bristol-Myers Squibb

It is always stressful for a drugmaker when it has to face patents for some of its prized products. This is what is happening with Bristol-Myers Squibb. The company’s cancer drug Revlimid — its best-selling drug last year — is currently losing sales in the US due to generic competition that began this year. The second quarter, although accounting for the impact of foreign exchange, Bristol-Myers revenue increased 5% compared to the year-ago period.

Thankfully, Bristol-Myers can deal with this and other upcoming patent exclusivity pitfalls. In April, the US Food and Drug Administration (FDA) approved the company’s Camzios, a new drug to treat New York Heart Association Class II-III obstructive hypertrophic cardiomyopathy (a heart-related disorder). In March, it won approval in the US for another brand-new product, the cancer drug, Opdualag.

Just last year, Bristol-Myers Brynzi, another cancer drug, won regulatory approval in the US for the first time. , Plaque Psoriasis Treatment Ducravasitinib.

And that’s not counting the company’s existing products — such as the cancer drug Opdivo — that continue to receive new indications. With a solid pipeline continuing to expand Bristol-Myers’ revenue base, the company’s future looks bright, even as we face its current downturn and economic headwinds.

Bristol-Myers is also a solid, dividend-paying stock. It currently offers an average yield of 2.93%. Be it for passive income or to help deliver market-returned investors, Bristol-Myers is a strong candidate.

Prosper Junior Bikini There are positions at Johnson & Johnson. The Motley Fool has posts and recommends Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has one Disclosure Policy,

Be the first to comment

Leave a Reply

Your email address will not be published.


*